Evidence map›Paper›PMID 39417182›Full record

ArticleAmerican journal of cancer research2024

Uncovering the role of FXYD3 as a potential oncogene and early biomarker in pancreatic cancer.

Ke Xin Yee, Yu-Cheng Lee, Hieu Duc Nguyen, Ming-Yao Chen, Yi-Chun Ni, Yung-Fu Wu, Kuen-Haur Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Early cancer diagnosisWorld journal of gastrointestinal oncology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ke Xin YeePhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University-Shuang Ho Campus New Taipei 235, Taiwan.
Yu-Cheng LeeGraduate Institute of Medical Sciences, College of Medicine, Taipei Medical University Taipei 11031, Taiwan.
Hieu Duc NguyenPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University-Shuang Ho Campus New Taipei 235, Taiwan.
Ming-Yao ChenDivision of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Taipei Medical University Taipei 110, Taiwan.
Yi-Chun NiPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University-Shuang Ho Campus New Taipei 235, Taiwan.
Yung-Fu WuDepartment of Medical Research, Tri-Service General Hospital, National Defense Medical Center Taipei 114, Taiwan.
Kuen-Haur LeePhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University-Shuang Ho Campus New Taipei 235, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is an aggressive cancer with silent symptoms and high mortality with less than 11% of the 5-year survival rate. Until now, the significance of genes as clinical biomarkers in the early stages of pancreatic cancer has not been fully understood. Hence, this study aims to reveal the significant genes in the early stages of pancreatic cancer using bioinformatic analysis and

Indexed as

biomarkerearly stagesFXYD3metastasisPancreatic cancer

Identifiers

PMID39417182
PMCPMC11477818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.